Pacira BioSciences, Inc. (PCRX)
| Market Cap | 1.03B |
| Revenue (ttm) | 726.41M |
| Net Income (ttm) | 7.03M |
| Shares Out | 40.49M |
| EPS (ttm) | 0.16 |
| PE Ratio | 160.99 |
| Forward PE | 9.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 321,776 |
| Open | 25.78 |
| Previous Close | 25.55 |
| Day's Range | 25.26 - 26.14 |
| 52-Week Range | 18.80 - 27.64 |
| Beta | 0.20 |
| Analysts | Strong Buy |
| Price Target | 30.25 (+19.05%) |
| Earnings Date | Apr 30, 2026 |
About PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price target is $30.25, which is an increase of 19.05% from the latest price.
News
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs -- -- Findings show significant reductions in opioid consumption, healthcare res...
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the li...
Pacira BioSciences Transcript: 25th Annual Needham Virtual Healthcare Conference
The conference highlighted strong 2025 financials, robust growth in EXPAREL, and the strategic 5x30 plan targeting five pillars by 2030. Key pipeline milestones, expanded partnerships, and improved reimbursement are expected to drive future growth and market leadership.
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lo...
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the li...
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWI...
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Years [i] ; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30% [ii] ; The Company's Underperf...
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
-- Issues Statement in Response to DOMA's Nomination of Director Candidates -- -- No Shareholder Action Required at This Time --
Pacira BioSciences Transcript: Barclays 28th Annual Global Healthcare Conference
The company is executing its 5x30 strategy, achieving strong volume growth for EXPAREL, expanding payer coverage, and signing major partnerships. Key pipeline milestones and international deals are expected to drive future growth, while financial discipline and focused sales efforts support margin expansion.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pat...
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the li...
Pacira BioSciences Earnings Call Transcript: Q4 2025
2025 saw record revenue and gross margins, driven by EXPAREL growth, expanded payer coverage, and strategic partnerships. 2026 guidance projects continued steady growth, with new pipeline milestones and ex-U.S. revenues expected in 2027.
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years —
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv...
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted n...
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the indust...
Pacira BioSciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company reported strong growth, expanded its IP estate, and advanced its 5x30 strategy, including new partnerships and pipeline progress. NOPAIN legislation and increased market access are driving steady volume growth, while upcoming data readouts for key products are expected to further support momentum.
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences,...
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv...
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
Restates Position that Pacira's Board Should Conduct Formal Sales Process of the Business Considers Current Executive Compensation and Spending Exorbitant and Unmerited Questions Whether the Board Has...
Pacira BioSciences Transcript: Piper Sandler 37th Annual Healthcare Conference
Three marketed non-opioid pain products drive strong revenue, with a robust pipeline including PCRX-201 gene therapy. Strategic goals target patient growth, margin improvement, and global expansion, while regulatory changes and focused sales strategies support future growth.
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to de...
Pacira BioSciences Transcript: Jefferies London Healthcare Conference 2025
The company targets double-digit growth and margin expansion by 2030, driven by Exparel’s accelerating adoption, new reimbursement catalysts, and operational efficiencies. Pipeline progress, especially with PCRX-201, and strategic partnerships are expected to further boost growth.
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv...